Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data

Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator